Abstract
Epidemiological studies suggest that vitamin D protects against prostate cancer, although evidence is limited and inconsistent. We investigated associations of circulating total 25-hydroxyvitamin D (25(OH)D) with prostate specific antigen-detected prostate cancer in a case-control study nested within the prostate testing for cancer and treatment (ProtecT) trial. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) quantifying the association between circulating total 25(OH)D and prostate cancer. In case-only analyses, we used unconditional logistic regression to quantify associations of total 25(OH)D with stage (advanced vs. localized) and Gleason grade (high-grade (=7) vs. low-grade (
Original language | English |
---|---|
Pages (from-to) | 1187-1196 |
Number of pages | 10 |
Journal | International Journal of Cancer |
Volume | 131 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 Sep 2012 |
Structured keywords
- BTC (Bristol Trials Centre)
- Centre for Surgical Research
Keywords
- prostate cancer
- vitamin D
- 25-hydroxyvitamn D
- VITAMIN-D STATUS
- UNITED-STATES
- AFRICAN-AMERICANS
- SUBSEQUENT RISK
- MEN
- MORTALITY
- 1,25-DIHYDROXYVITAMIN-D
- D-1-ALPHA-HYDROXYLASE
- EPIDEMIOLOGY
- CALCITRIOL